Scottsdale, Arizona 8/12/2008 12:24:20 AM
News / Finance

QualityStocks News – EXACT Sciences Corporation (EXAS) Announces Published Study Results for the Company’s Colorectal Cancer Detection Technology

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

 

We would like to highlight EXACT Sciences Corp. (NASDAQ: EXAS). The company is an applied genomics company that develops deoxyribonucleic acid (DNA)-based technologies for use in the detection of cancer. The Company has selected colorectal cancer as the first application of its technologies. The Company has licensed certain of its technologies, on an exclusive basis through December 2010, to Laboratory Corporation of America Holdings (LabCorp) in connection with a commercial testing service that is marketed in the United States under the name PreGen-Plus.

 

In the company’s recent news,

 

EXACT Sciences Corporation, a research and development company focused on developing non-invasive screening technologies for early detection of colorectal cancer, announced published results of a comprehensive colorectal cancer detection study in which stool and blood plasma were individually assessed to determine which type of testing was more accurate in detecting the disease.

 

The study results showed 92 percent sensitivity for detecting colorectal cancer in stool samples. Utilizing state-of-the-art BEAMing DNA detection technology from Johns Hopkins University, the study results showed that stool-based DNA testing outperformed blood plasma testing, especially for the detection of early-stage colorectal cancers. According to the study, stool-based testing provides more accuracy due to its immediate contact with the colorectal cancers and polyps in the colon.

 

Executive management of EXACT Sciences Corporation is pleased by the latest results as they underscore the early detection power that is achievable when combining advanced detection techniques with a DNA target-rich environment such as stool samples. The results of this latest study suggest that stool is the more reliable and robust source of mutated DNA when compared to blood plasma.

 

About QualityStocks

 

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

 

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

 

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.